CN102247373A - 一种甲硫氨酸维b1化合物的组合物 - Google Patents
一种甲硫氨酸维b1化合物的组合物 Download PDFInfo
- Publication number
- CN102247373A CN102247373A CN2011102193679A CN201110219367A CN102247373A CN 102247373 A CN102247373 A CN 102247373A CN 2011102193679 A CN2011102193679 A CN 2011102193679A CN 201110219367 A CN201110219367 A CN 201110219367A CN 102247373 A CN102247373 A CN 102247373A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- methionine
- temperature
- dihydrate
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003495 thiamine Drugs 0.000 title claims abstract description 73
- 229930003451 Vitamin B1 Natural products 0.000 title claims abstract description 71
- 239000011691 vitamin B1 Substances 0.000 title claims abstract description 71
- 235000010374 vitamin B1 Nutrition 0.000 title claims abstract description 71
- 229930182817 methionine Natural products 0.000 title claims abstract description 39
- -1 methionine vitamin B1 compound Chemical class 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000000243 solution Substances 0.000 claims abstract description 39
- 150000004683 dihydrates Chemical class 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 25
- 238000003756 stirring Methods 0.000 claims abstract description 24
- 239000007864 aqueous solution Substances 0.000 claims abstract description 14
- 238000002347 injection Methods 0.000 claims abstract description 14
- 239000007924 injection Substances 0.000 claims abstract description 14
- 229940088594 vitamin Drugs 0.000 claims abstract description 14
- 229930003231 vitamin Natural products 0.000 claims abstract description 14
- 235000013343 vitamin Nutrition 0.000 claims abstract description 14
- 239000011782 vitamin Substances 0.000 claims abstract description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 13
- 229930195725 Mannitol Natural products 0.000 claims abstract description 12
- 239000000594 mannitol Substances 0.000 claims abstract description 12
- 235000010355 mannitol Nutrition 0.000 claims abstract description 12
- 238000001291 vacuum drying Methods 0.000 claims abstract description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract 11
- 238000004108 freeze drying Methods 0.000 claims description 61
- 238000009413 insulation Methods 0.000 claims description 40
- 229930003270 Vitamin B Natural products 0.000 claims description 39
- 235000019156 vitamin B Nutrition 0.000 claims description 39
- 239000011720 vitamin B Substances 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 239000000047 product Substances 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- 238000009833 condensation Methods 0.000 claims description 10
- 230000005494 condensation Effects 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 238000010792 warming Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 8
- 229910052782 aluminium Inorganic materials 0.000 claims description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical class O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 239000008227 sterile water for injection Substances 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000013112 stability test Methods 0.000 abstract description 5
- 238000002425 crystallisation Methods 0.000 abstract description 4
- 230000008025 crystallization Effects 0.000 abstract description 4
- 238000004821 distillation Methods 0.000 abstract 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 45
- 238000012360 testing method Methods 0.000 description 26
- 238000001228 spectrum Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001757 thermogravimetry curve Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 2
- 230000007872 intrahepatic cholestasis Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229950001485 cocarboxylase Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102193679A CN102247373B (zh) | 2011-08-02 | 2011-08-02 | 一种甲硫氨酸维b1化合物的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102193679A CN102247373B (zh) | 2011-08-02 | 2011-08-02 | 一种甲硫氨酸维b1化合物的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102247373A true CN102247373A (zh) | 2011-11-23 |
CN102247373B CN102247373B (zh) | 2012-08-22 |
Family
ID=44975180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011102193679A Expired - Fee Related CN102247373B (zh) | 2011-08-02 | 2011-08-02 | 一种甲硫氨酸维b1化合物的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102247373B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641272A (zh) * | 2012-04-17 | 2012-08-22 | 湖北济生医药有限公司 | 甲硫氨酸维生素b1的药物组合物及其制备方法 |
CN102743350A (zh) * | 2012-07-30 | 2012-10-24 | 刘时灵 | 甲硫氨酸维生素b1组合物针剂 |
CN104055777A (zh) * | 2014-07-01 | 2014-09-24 | 哈药集团生物工程有限公司 | 一种含有甲硫氨酸维b1的冻干药物组合物及制备方法 |
CN107773532A (zh) * | 2017-06-22 | 2018-03-09 | 北京立时达药业有限公司 | 一种维生素b1注射液及其生产方法 |
CN110898005A (zh) * | 2019-12-30 | 2020-03-24 | 滨州医学院附属医院 | 一种减毒增效的长春瑞滨注射液及其抗肺癌应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1663567A (zh) * | 2004-03-05 | 2005-09-07 | 罗靖 | 复方甲硫氨酸维生素b1冻干粉针制剂及其制备方法 |
CN1903204A (zh) * | 2005-07-27 | 2007-01-31 | 武汉同源药业有限公司 | 注射用甲硫氨酸维b1及其制备方法 |
CN102079767A (zh) * | 2009-11-26 | 2011-06-01 | 天津金耀集团有限公司 | 卤甲松单水合物的制备方法 |
-
2011
- 2011-08-02 CN CN2011102193679A patent/CN102247373B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1663567A (zh) * | 2004-03-05 | 2005-09-07 | 罗靖 | 复方甲硫氨酸维生素b1冻干粉针制剂及其制备方法 |
CN1903204A (zh) * | 2005-07-27 | 2007-01-31 | 武汉同源药业有限公司 | 注射用甲硫氨酸维b1及其制备方法 |
CN102079767A (zh) * | 2009-11-26 | 2011-06-01 | 天津金耀集团有限公司 | 卤甲松单水合物的制备方法 |
Non-Patent Citations (1)
Title |
---|
《药剂学》 20010430 毕殿洲主编 药剂学 人民卫生出版社 第九章第五节 7-10 , * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641272A (zh) * | 2012-04-17 | 2012-08-22 | 湖北济生医药有限公司 | 甲硫氨酸维生素b1的药物组合物及其制备方法 |
CN102641272B (zh) * | 2012-04-17 | 2015-06-03 | 湖北济生医药有限公司 | 甲硫氨酸维生素b1的药物组合物及其制备方法 |
CN102743350A (zh) * | 2012-07-30 | 2012-10-24 | 刘时灵 | 甲硫氨酸维生素b1组合物针剂 |
CN102743350B (zh) * | 2012-07-30 | 2013-06-19 | 刘时灵 | 甲硫氨酸维生素b1组合物针剂及其制备方法 |
CN104055777A (zh) * | 2014-07-01 | 2014-09-24 | 哈药集团生物工程有限公司 | 一种含有甲硫氨酸维b1的冻干药物组合物及制备方法 |
CN104055777B (zh) * | 2014-07-01 | 2016-03-30 | 哈药集团生物工程有限公司 | 一种含有甲硫氨酸维b1的冻干药物组合物 |
CN107773532A (zh) * | 2017-06-22 | 2018-03-09 | 北京立时达药业有限公司 | 一种维生素b1注射液及其生产方法 |
CN110898005A (zh) * | 2019-12-30 | 2020-03-24 | 滨州医学院附属医院 | 一种减毒增效的长春瑞滨注射液及其抗肺癌应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102247373B (zh) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102247373B (zh) | 一种甲硫氨酸维b1化合物的组合物 | |
CN101791310B (zh) | 长春西汀药物组合物及其制备方法 | |
CN102258531B (zh) | 一种含有环磷腺苷与葡甲胺的药物组合物及其制备方法 | |
CN102512437B (zh) | 一种脂溶性维生素注射液(i)和注射用水溶性维生素的药物组合物及其制法 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN101455631A (zh) | 环磷腺苷葡胺注射液及其制备工艺 | |
CN104434819A (zh) | 注射用乙酰谷酰胺粉针剂药物组合物和制法 | |
CN104208020B (zh) | 一种盐酸罗哌卡因注射液及其制备方法 | |
CN101181243A (zh) | 一种环磷腺苷冻干制剂及其制备方法 | |
CN103040855B (zh) | 一种磷酸氟达拉滨的药物组合物及其制备方法 | |
CN102429864A (zh) | 一种脂溶性维生素注射液(ii)和注射用水溶性维生素的药物组合物及其制法 | |
CN102499939B (zh) | 一种注射用脂溶性维生素和注射用水溶性维生素的药物组合物及其制法 | |
CN102743350B (zh) | 甲硫氨酸维生素b1组合物针剂及其制备方法 | |
CN103417474B (zh) | 含有二丁酰环磷腺苷钙的注射用组合物 | |
CN102106846A (zh) | 左旋盐酸艾司洛尔药物组合物及其制备方法 | |
CN102247372B (zh) | 一种含有甲硫氨酸的药物组合物及制备方法 | |
CN101810620B (zh) | 甲硫氨酸维生素b1组合物针剂及其制备方法 | |
CN107019675A (zh) | 注射用环磷腺苷冻干粉针剂药物组合物及质控方法和制法 | |
CN104042645B (zh) | 复方氨基酸注射液 | |
CN102757471A (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
CN105853347A (zh) | 一种左卡尼汀的组合物及其制备方法 | |
CN103040765A (zh) | 含三磷酸腺苷二钠的药物组合物及其制备方法 | |
CN106074399B (zh) | 一种帕瑞昔布钠冻干制剂及其制备方法 | |
CN104739759A (zh) | 一种含有米力农化合物的药物组合物 | |
CN102940623A (zh) | 一种左卡尼汀化合物的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111123 Assignee: JIANGXI YINTAO PHARMACEUTICAL CO.,LTD. Assignor: Zhou Xiaodong Contract record no.: 2013360000140 Denomination of invention: Composition of methionine vitamin B1 compound Granted publication date: 20120822 License type: Common License Record date: 20130930 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111123 Assignee: CHENGDU HAITONG PHARMACEUTICAL CO.,LTD. Assignor: Zhou Xiaodong Contract record no.: 2014360000026 Denomination of invention: Composition of methionine vitamin B1 compound Granted publication date: 20120822 License type: Common License Record date: 20140128 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111123 Assignee: JIANGXI YINTAO PHARMACEUTICAL CO.,LTD. Assignor: Zhou Xiaodong Contract record no.: 2016360000001 Denomination of invention: Composition of methionine vitamin B1 compound Granted publication date: 20120822 License type: Common License Record date: 20160107 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171024 Address after: 331200 No. 26, building E1, building 43, Fucheng Town, Fucheng street, Zhangshu City, Jiangxi, Yichun Patentee after: Zhangshu Consulting Service Center Address before: 330006 Xihu District, Nanchang City, Jiangxi Province, Chazikou Pearl Plaza, Block h 1709 Patentee before: Zhou Xiaodong |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 |
|
CF01 | Termination of patent right due to non-payment of annual fee |